FIA
KROS icon

FNY Investment Advisers’s Keros Therapeutics KROS Stock Holding History

FNY Investment Advisers’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,500
Closed -$39K – 1197
2025
Q3 		$39K Hold
2,500
– – 0.01% 551
2025
Q2 		$33K Hold
2,500
– – 0.01% 486
2025
Q1 		$25K Buy
+2,500
New +$29K 0.02% 368

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

FNY Investment Advisers's KROS Position: Q4 2025 in Review

FNY Investment Advisers sold out of Keros Therapeutics (KROS) in Q4 2025, closing a stake of 2,500 shares — an estimated $39K sold.

FNY Investment Advisers first reported a position in KROS in Q1 2025 and held it in 3 quarters. The position peaked at $39K in Q3 2025. 166 funds tracked by Wall St. Rank hold KROS as of Q4 2025.

  • FNY Investment Advisers reported no remaining Keros Therapeutics position as of Q4 2025 after selling out during the quarter.
  • FNY Investment Advisers sold 2,500 Keros Therapeutics shares in Q4 2025, an estimated $39K.
  • FNY Investment Advisers first reported a position in Keros Therapeutics in Q1 2025 and held it in 3 quarters.
  • FNY Investment Advisers's Keros Therapeutics position peaked at $39K in Q3 2025.
  • 166 funds tracked by Wall St. Rank held Keros Therapeutics as of Q4 2025.

Based on FNY Investment Advisers's 13F filing for Q4 2025, filed 16 Jan 2026.